Figure 4.
(A) Overall referrals for patient financial resources; (B) awareness of and referrals to patient financial resources.
Notes: No significant difference between respondents who do and do not believe patient adherence significantly impacts treatment outcome in the proportion who routinely refer patients to at least one program, the proportion familiar with at least one program (though not routinely referring patients to any), and the proportion being familiar with any program, X2 (2, N=126) =0.214, P=0.898. *Others: additional financial information found through the endocrine societies of individual countries/regions. #Significant overall difference (chi-square P=0.004) between B and C; significant pairwise differences (P<0.05) for “familiar with, but do not routinely refer” and for “not familiar with.” Financial assistance for lanreotide (http://acromegaly.somatulinedepot.com/resources/copay-savings-programs); Financial assistance for octreotide and pasireotide (1-877-LAR-IN FO, peak Pituitary Education, Access, and Knowledge, www.endocrineaccessnow.com).